Jennison Associates LLC Has $1.27 Million Holdings in Haemonetics Corporation $HAE

Jennison Associates LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 86.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,536 shares of the medical instruments supplier’s stock after buying an additional 10,433 shares during the quarter. Jennison Associates LLC’s holdings in Haemonetics were worth $1,270,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new stake in Haemonetics during the fourth quarter worth $26,000. True Wealth Design LLC grew its position in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the period. Leonteq Securities AG acquired a new position in shares of Haemonetics during the 4th quarter worth about $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Haemonetics in the 4th quarter valued at about $34,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HAE shares. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and raised their target price for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. BTIG Research restated a “buy” rating and issued a $84.00 price objective on shares of Haemonetics in a research note on Friday, June 26th. Mizuho raised their price objective on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Stock Performance

NYSE HAE opened at $77.95 on Thursday. The stock has a market cap of $3.54 billion, a PE ratio of 38.59, a P/E/G ratio of 1.57 and a beta of 0.52. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm has a 50-day moving average of $71.90 and a 200-day moving average of $66.10. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, sell-side analysts anticipate that Haemonetics Corporation will post 5.21 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.